The use of non-insulin anti-diabetic agents to improve glycemia without hypoglycemia in the hospital setting: Focus on incretins

Current Diabetes Reports

Volumn 14, Issue 3, 2014, Pages

  Schwartz, Stanley ^b,c   Defronzo, Ralph A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NONE   (United States)

Author keywords

DPP 4 inhibitors; GLP 1 receptor agonists; Glycemia; Hypoglycemia; In hospital diabetes control; Incretins; Intensive insulin therapy; Noninsulin anti diabetic agents

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE;

ALTERNATIVE MEDICINE; ARTICLE; CRITICALLY ILL PATIENT; DIABETIC PATIENT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE QUALITY; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; INTENSIVE CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; HOSPITALIZATION; REVIEW;

HOSPITALIZATION; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN;

EID: 84893200678     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0466-9     Document Type: Article

References (67)

1. CDC Website. Available at: http://www.cdc.gov/diabetes/statistics/dmany/ fig1.htm. Accessed 18 May 2013.
2. Hogan P, Dall T, Nikolov P. American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917-32. (Pubitemid 36929365)
3. Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG, et al. American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27:553-91. (Pubitemid 38174086)
4. Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650-61.
5. van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-61. (Pubitemid 43200296)
6. Finfer S, Chittock DR, Su SY, et al. NICESUGAR Study Investigators. Intensive vs conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283-97.
7. Brunkhorst FM, Engel C, Bloos F, et al. German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125-39.
8. Preiser JC, Devos P, Ruiz-Santana S, Mélot C, Annane D, Groeneveld J, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med. 2009;35:1738-48.
9. Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care. 2009;32:1153-7.
10. Duggal R, Menkes DB. Evidence-based medicine in practice. Int J Clin Pract. 2011;65:639-44.
11. Falciglia M, Freyberg RW, Almenoff PL, D'Alessio DA, Render ML. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Crit Care Med. 2009;37:3001-9.
12. Muhlestein JB, Anderson JL, Horne BD, Lavasani F, Maycock A, Bair TL, et al. Intermountain Heart Collaborative Study Group. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J. 2003;146:351-8. (Pubitemid 36951783)
13. Furnary AP, Wu Y. Clinical effects of hyperglycemia in the cardiac surgery population: the Portland Diabetic Project. Endocr Pract. 2006;12 Suppl 3:22-6. (Pubitemid 44963589)
14. Van Den B, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-67.
15. Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650-61. (Pubitemid 40516876)
16. Griesdale DE, de Souza RJ, van Dam RM, Heyland DK, Cook DJ, Malhotra A, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. Can Med Assoc J. 2009;180:821-7.
17. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA. 2008;300:933-44.
18. Egi M, Bellomo R, Stachowski E, French CJ, Hart GK, Taori G, et al. Hypoglycemia and outcome in critically ill patients. Mayo Clin Proc. 2010;85:217-24.
19. Asadollahi K, Hastings IM, Beeching NJ, Gill GV. Laboratory risk factors for hospital mortality in acutely admitted patients. Q J Med. 2007;100:501-7. (Pubitemid 47241916)
20. Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, et al. TIMI Study Group J. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005;46:178-80. (Pubitemid 40905149)
21. Kosiborod M, Inzucchi SE, Krumholz HM, Xiao L, Jones PG, Fiske S, et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation. 2008;117:1018-27.
22. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 2010;33:1389-94.
23. Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycemia in type 1 diabetes - the 'dead in bed' syndrome revisited. Diabetologia. 2009;52:42-5.
24. Tremblay A, Pinsard D, Coveney S, Catellier C, Laferriere G, Richard D, et al. Counter-regulatory response to insulin-induced hypoglycemia in trained and non-trained humans. Metabolism. 1990;39:1138-43. (Pubitemid 20376343)
25. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes. 2003;26:1485-9. (Pubitemid 36929183)
26. Lindstrom T, Jorfeldt L, Tegler L, Arnqvist HJ. Hypoglycemia and cardiac arrhythmias in patients with type 2 diabetes mellitus. Diabetes Med. 1992;9:536-41.
27. Heller SR. Abnormalities of the electrocardiogram during hypoglycemia: the cause of the dead in bed syndrome? Int J Clin Pract. 2002;129(Suppl):27-32.
28. http:www.psqh.com/Julyaugust-2009/164%20data-trends-july-august-2009. html.
29. The ACE/ADA Task Force on In-patient Diabetes. American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. Diabetes Care. 2006;29:1955-62. (Pubitemid 44156662)
30. Inzucchi SE, Siegel MD. Glucose control in the ICU - how tight is too tight? N Engl J Med. 2009;26:1346-9.
31. Umpierrez GE, Korytkowski M. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? Insulin therapy has proven itself and is considered the mainstay of treatment. Diabetes Care. 2013;36:2112-7.
32. Jacobi J et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med. 2012;40:3251-76.
33. Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, et al. Management of hyperglycemia in hospitalized patients in noncritical care setting: an endocrine society clinical practice guideline. Endocrine Society. J Clin Endocrinol Metab. 2012;97:16-38.
34. Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007;30:2181-6. (Pubitemid 47359011)
35. Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011;34:256-61.
36. Nauck MA, Vilsboll T, Gallwitz B, Garber A, Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care. 2009;32:S223-31.
37. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54:10-8.
38. van Raalte DH, van Genugten RE, Linssen MM, Ouwens DM, Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid- induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care. 2011;34:412-7.
39. Ranta F, Avram D, Berchtold S, Dufer M, Drews G, Lang F, et al. Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes. 2006;55:1380-90. (Pubitemid 44195377)
40. Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. Am J Med. 2011;124:S35-53.
41. Fadini G. Cardiovascular effects off DPP-4 Inhibition. Vasc Pharmacol. 2011;55:10-3.
42. Ratner R, Han J, Nicewarmer D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011;10:22-32.
43. Sanon S, Patel R, Eshelbrenner C, Sanon VP, Alhaddad M, Oliveros R, et al. Acute coronary syndrome in patients with diabetes mellitus: perspectives of an interventional cardiologist. Am J Cardiol. 2012;110(9 Suppl):13B-23B.
44. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circulation. 2010;3:195-201.
45. Monami M, Cremasco F, Lamanna C, Colombi C, Desideri CM, Iacomelli I, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res. 2011;2011:215764.
46. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide vs sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24:2943-52.
47. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. Liraglutide vs sitagliptin for patients with type 2 diabetes who did not have adequate glycemic control with metformin: a 26-week, randomized, parallel-group, open-label trial. Lancet. 2010;375:147-56.
48. Schwartz S, Kohl BA. Type 2 diabetes mellitus and the cardio-metabolic syndrome: impact of incretin-based therapies. Diabetes Metab Syndr Obes. 2010;3:227-42.
49. Schwartz S, Kohl BA. Intraoperative glycemic control with intravenous GLP-1 in cardiac surgery. Presented ASCCA; 2010. [Abstract].
50. Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck MA, et al. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med. 2004;32:848-51. (Pubitemid 38340086)
51. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagonlike peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962-5. (Pubitemid 38282847)
52. Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ Jr, Maher TD, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;100:824-9. (Pubitemid 47268274)
53. Mussig K, Oncu A, Lindauer P, Heininger A, Aebert H, Unertl K, et al. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol. 2008;102:646-7.
54. Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, et al. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept. 2004;118:89-97. (Pubitemid 38167370)
55. Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz. The effect of exogenous glucagon-like peptide-1 on the glycemic response to small intestinal nutrient in the critically ill: a randomized double-blind placebo-controlled cross over study. Crit Care. 2009;13:R67.
56. Sourij H, Schmölzer I, Kettler-Schmut E, Eder M, Pressl H, Decampo A, et al. Efficacy of a continuous GLP-1 infusion compared with a structured insulin infusion protocol to reach normoglycemia in nonfasted type 2 diabetic patients: a clinical pilot trial. Diabetes Care. 2009;32:1669-71.
57. Deane AM, Chapman MJ, Horowitz M. The use of glucagon-like peptide-1 analogues in the critically ill. Crit Care. 2010;14:1004-7.
58. Kovalaske MA, Gandhi GY. Incretins in the ICU: is insulin on its way out? Crit Care. 2009;13:161. Proposal from others on same topic, albeit without understanding mechanism of effectiveness based on overcoming suppression of insulin secretion by steroids and calmodulin inhibitors.
59. De Caterinal R, Madonna R, Sourij H, Wascher T. Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. Eur Heart J. 2010;31:1557-64.
60. Marso SP, Al-Amoodi M, Riggs L, House J, Peterman D, Kennedy K, et al. Administration of intravenous exenatide to patients with sustained hyperglycemia in the coronary ICU. Diabetes. 2011;60:A75.
61. Lonborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491-9.
62. Mecott GA, Herndon DN, Kulp GA, Brooks NC, Al-Mousawi AM, Kraft R, et al. The use of exenatide in severely burned pediatric patients. Crit Care. 2010;14(4):R153. doi. 10.1186/cc9222. Best study of clinically available GLP-1 in hospital, illustrated proposed benefits outlined in our article.
63. Katagiri N. Peri-operative therapy for Japanese subjects with T2DM; ADA Poster #1039-P. Chicago; 2013.
64. Umpierrez GE, Gianchandani R, Smiley D, Jacobs S, Wesorick DH, Newton C, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized controlled study Diabetes Care. 2013;36(11):3430-5. doi: 10.2337/dc13-0277. Only randomized prospective trial using incretin in-hospital.
65. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, et al. NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-long acting basal insulin, vs insulin glargine in basal-bolus treatment with mealtime insulin as part in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomized, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1498-507.
66. Abuannadi M, Kosiborod M, Riggs L, House JA, Hamburg MS, Kennedy KF, et al. Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. Endocr Pract. 2013;19:81-90.
67. Ellero C, Han J, Bhavsar S, Cirincione BB, Deyoung MB, Gray AL, et al. Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel group, single-dose study in healthy subjects. Diabetes Med. 2010;27:1168-73.